Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028545661> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2028545661 endingPage "127" @default.
- W2028545661 startingPage "123" @default.
- W2028545661 abstract "To seek the cutoff value of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) that is necessary to achieve remission under the new Boolean-based criteria, we analyzed the data for 285 patients with rheumatoid arthritis registered between May 2008 and November 2009 by the Michinoku Tocilizumab Study Group and observed for 1 year after receiving tocilizumab (TCZ) in real clinical practice. Remission rates under the DAS28-ESR criteria and the Boolean criteria were assessed every 6 months after the first TCZ dose. The DAS28-ESR cutoff value necessary to achieve remission under the new criteria was analyzed by receiver operating characteristic (ROC) analysis. Data were analyzed using last observation carried forward. After 12 months of TCZ use, remission was achieved in 164 patients (57.5 %) by DAS28-ESR and 71 patients (24.9 %) under the new criteria for clinical trials. CRP levels scarcely affected remission rates, and the difference between remission rates defined by DAS28-ESR and by the new criteria was mainly due to patient global assessment (PGA). Improvement of PGA was inversely related to disease duration. ROC analysis revealed that the DAS28-ESR cutoff value necessary to predict remission under the new criteria for clinical trials was 1.54, with a sensitivity of 88.7 %, specificity of 85.5 %, positive predictive value of 67.0 %, and negative predictive value of 95.8 %. A DAS28-ESR cutoff value of 1.54 may be reasonable to predict achievement of remission under the new Boolean-based criteria for clinical trials in patients receiving TCZ." @default.
- W2028545661 created "2016-06-24" @default.
- W2028545661 creator A5042340344 @default.
- W2028545661 creator A5090428843 @default.
- W2028545661 date "2012-10-23" @default.
- W2028545661 modified "2023-09-25" @default.
- W2028545661 title "The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab" @default.
- W2028545661 cites W1993510043 @default.
- W2028545661 cites W2006008590 @default.
- W2028545661 cites W2016527844 @default.
- W2028545661 cites W2099334955 @default.
- W2028545661 cites W2108811033 @default.
- W2028545661 cites W2110177517 @default.
- W2028545661 cites W2114308202 @default.
- W2028545661 cites W2117810266 @default.
- W2028545661 cites W2142085941 @default.
- W2028545661 cites W4249063051 @default.
- W2028545661 doi "https://doi.org/10.1007/s10067-012-2103-4" @default.
- W2028545661 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3558670" @default.
- W2028545661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23090655" @default.
- W2028545661 hasPublicationYear "2012" @default.
- W2028545661 type Work @default.
- W2028545661 sameAs 2028545661 @default.
- W2028545661 citedByCount "9" @default.
- W2028545661 countsByYear W20285456612013 @default.
- W2028545661 countsByYear W20285456612014 @default.
- W2028545661 countsByYear W20285456612015 @default.
- W2028545661 countsByYear W20285456612016 @default.
- W2028545661 countsByYear W20285456612017 @default.
- W2028545661 countsByYear W20285456612020 @default.
- W2028545661 crossrefType "journal-article" @default.
- W2028545661 hasAuthorship W2028545661A5042340344 @default.
- W2028545661 hasAuthorship W2028545661A5090428843 @default.
- W2028545661 hasBestOaLocation W20285456611 @default.
- W2028545661 hasConcept C121332964 @default.
- W2028545661 hasConcept C126322002 @default.
- W2028545661 hasConcept C198451711 @default.
- W2028545661 hasConcept C2777178219 @default.
- W2028545661 hasConcept C2777575956 @default.
- W2028545661 hasConcept C2778143017 @default.
- W2028545661 hasConcept C2778217198 @default.
- W2028545661 hasConcept C58471807 @default.
- W2028545661 hasConcept C62520636 @default.
- W2028545661 hasConcept C71924100 @default.
- W2028545661 hasConcept C90924648 @default.
- W2028545661 hasConceptScore W2028545661C121332964 @default.
- W2028545661 hasConceptScore W2028545661C126322002 @default.
- W2028545661 hasConceptScore W2028545661C198451711 @default.
- W2028545661 hasConceptScore W2028545661C2777178219 @default.
- W2028545661 hasConceptScore W2028545661C2777575956 @default.
- W2028545661 hasConceptScore W2028545661C2778143017 @default.
- W2028545661 hasConceptScore W2028545661C2778217198 @default.
- W2028545661 hasConceptScore W2028545661C58471807 @default.
- W2028545661 hasConceptScore W2028545661C62520636 @default.
- W2028545661 hasConceptScore W2028545661C71924100 @default.
- W2028545661 hasConceptScore W2028545661C90924648 @default.
- W2028545661 hasIssue "1" @default.
- W2028545661 hasLocation W20285456611 @default.
- W2028545661 hasLocation W20285456612 @default.
- W2028545661 hasLocation W20285456613 @default.
- W2028545661 hasLocation W20285456614 @default.
- W2028545661 hasOpenAccess W2028545661 @default.
- W2028545661 hasPrimaryLocation W20285456611 @default.
- W2028545661 hasRelatedWork W1984273828 @default.
- W2028545661 hasRelatedWork W1987294331 @default.
- W2028545661 hasRelatedWork W2035343580 @default.
- W2028545661 hasRelatedWork W2046399730 @default.
- W2028545661 hasRelatedWork W2064540460 @default.
- W2028545661 hasRelatedWork W2094304284 @default.
- W2028545661 hasRelatedWork W2317949227 @default.
- W2028545661 hasRelatedWork W2558297493 @default.
- W2028545661 hasRelatedWork W2636378421 @default.
- W2028545661 hasRelatedWork W2736593664 @default.
- W2028545661 hasVolume "32" @default.
- W2028545661 isParatext "false" @default.
- W2028545661 isRetracted "false" @default.
- W2028545661 magId "2028545661" @default.
- W2028545661 workType "article" @default.